BioVaxys Technology Corp. Launches LIFE Offering to Enhance Research and Development Efforts BioVaxys Technology Corp. has announced a non-brokered private placement offering to raise up to $1.6 million, aimed at advancing innovative immunotherapy research.

BioVaxys Technology Corp. Launches LIFE Offering to Enhance Research and Development Efforts #Vancouver #Immunotherapy #BioVaxys #DPX_Technology

BioVaxys and Horizon Technology Update Asset Purchase Agreement in Major Move for Immunotherapies BioVaxys Technology Corp. announces amendments to the Asset Purchase Agreement with Horizon Technology Finance Corp, enhancing their acquisition strategy and financial milestones.

BioVaxys and Horizon Technology Update Asset Purchase Agreement in Major Move for Immunotherapies #Canada #Vancouver #BioVaxys #DPX_Technology #Horizon

BioVaxys Technology Corp. Updates on Corporate Developments and Future Directions BioVaxys Technology Corp. presents an update on its strategic initiatives, pipeline developments, and partnerships aimed at advancing innovative therapies for cancer and other diseases.

BioVaxys Technology Corp. Updates on Corporate Developments and Future Directions #Canada #Vancouver #Cancer_Immunotherapy #DPX_Technology #BioVaxys_Technology

BioVaxys Technology Corp. Extends Closing Date for Private Placement Offering to Attract More Investors BioVaxys Technology Corp. announces an extension to the closing date for its non-brokered private placement, aimed at boosting investor participation.

BioVaxys Technology Corp. Extends Closing Date for Private Placement Offering to Attract More Investors #Canada #Vancouver #Immunotherapy #BioVaxys #DPX_Technology

BioVaxys Aims to Transform mRNA Vaccine Delivery with DPX Technology for Major Market Growth BioVaxys Technology Corp. is setting its sights on revolutionizing mRNA vaccine delivery with its DPX™ platform, poised for substantial market growth by 2030.

BioVaxys Aims to Transform mRNA Vaccine Delivery with DPX Technology for Major Market Growth #Canada #Vancouver #BioVaxys #DPX_Technology #mRNA_vaccines

BioVaxys Technology Corp. Completes Third Tranche of Private Placement Funding BioVaxys Technology Corp. successfully closes its third tranche of a private placement, raising $537,500. The funds are designated for working capital and strategic initiatives.

BioVaxys Technology Corp. Completes Third Tranche of Private Placement Funding #Canada #Vancouver #Private_Placement #BioVaxys #DPX_Technology

BioVaxys Technology Corp. Successfully Completes Second Tranche of Private Placement for Future Growth BioVaxys Technology Corp. has announced the completion of its second tranche in a private placement, securing $175,000 to further its mission in biopharmaceutical innovation.

BioVaxys Technology Corp. Successfully Completes Second Tranche of Private Placement for Future Growth #Canada #Vancouver #DPX_Technology #BioVaxys_Technology #Biovaxys_Shares

BioVaxys Expands Vaccine Development with Secured GMP-Grade Lipid Supply BioVaxys Technology Corp. has secured a significant supply of GMP-grade lipids to advance its DPX-based vaccine development, aiming for clinical trials.

BioVaxys Expands Vaccine Development with Secured GMP-Grade Lipid Supply #Canada #Vancouver #BioVaxys #DPX_Technology #GMP-grade_Lipid

BioVaxys Unveils Promising Findings on DPX Immune Platform at Cancer Vaccine Summit BioVaxys Technology Corp. presented promising new data regarding its DPX immune educating platform, highlighting its effectiveness in cancer vaccines.

BioVaxys Unveils Promising Findings on DPX Immune Platform at Cancer Vaccine Summit #Canada #Vancouver #BioVaxys #DPX_Technology #Cancer_Vaccine